Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
· scancell holdings plc
AI Briefing
- iSCIB1+ receives FDA Fast Track Designation for advanced melanoma, Phase 2 SCOPE trial shows 77% PFS at 20 months, additional PFS and OS data expected in H1 2027.
Advertisement